Codexis to Report Second Quarter 2025 Financial Results on August 13
Codexis (NASDAQ: CDXS), a provider of enzymatic solutions for therapeutic manufacturing, has scheduled its second quarter 2025 financial results announcement for August 13, 2025, after market close.
The company will host a conference call and webcast at 4:30 PM ET to discuss results and provide business updates. Investors can access the webcast through Codexis' Investor Relations website, where it will remain available for 90 days. For the live call, participants can dial 877-705-2976 (domestic) or 201-689-8798 (international).
Codexis (NASDAQ: CDXS), fornitore di soluzioni enzimatiche per la produzione terapeutica, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 13 agosto 2025, dopo la chiusura del mercato.
L'azienda terr脿 una conference call e una webcast alle 16:30 ET per discutere i risultati e fornire aggiornamenti aziendali. Gli investitori potranno accedere alla webcast tramite il sito web delle Relazioni con gli Investitori di Codexis, dove rester脿 disponibile per 90 giorni. Per partecipare alla chiamata in diretta, 猫 possibile chiamare il numero 877-705-2976 (nazionale) o 201-689-8798 (internazionale).
Codexis (NASDAQ: CDXS), proveedor de soluciones enzim谩ticas para la fabricaci贸n terap茅utica, ha programado el anuncio de resultados financieros del segundo trimestre de 2025 para el 13 de agosto de 2025, despu茅s del cierre del mercado.
La compa帽铆a realizar谩 una llamada conferencia y una transmisi贸n en vivo a las 4:30 PM ET para discutir los resultados y brindar actualizaciones comerciales. Los inversores pueden acceder a la transmisi贸n en vivo a trav茅s del sitio web de Relaciones con Inversores de Codexis, donde estar谩 disponible por 90 d铆as. Para la llamada en vivo, los participantes pueden marcar 877-705-2976 (nacional) o 201-689-8798 (internacional).
Codexis (NASDAQ: CDXS)電� 旃橂鞝� 鞝滌“毳� 鞙勴暅 須唽 靻旊（靺� 鞝滉车鞐呾泊搿�, 2025雲� 2攵勱赴 鞛 鞁れ爜 氚滍憸毳� 2025雲� 8鞗� 13鞚� 鞛� 毵堦皭 頉勳棎 鞓堨爼頃橁碃 鞛堨姷雼堧嫟.
须岇偓电� 霃欕秬 響滌鞁� 鞓ろ泟 4鞁� 30攵�鞐� 鞁れ爜 雲检潣 氚� 靷梾 鞐呺嵃鞚错姼毳� 鞙勴暅 旎嵓霟办姢 旖滉臣 鞗轨簮鞀ろ姼毳� 歆勴枆頃� 鞓堨爼鞛呺媹雼�. 韴瀽鞛愲摛鞚� Codexis 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 鞗轨簮鞀ろ姼鞐� 鞝戩啀頃� 靾� 鞛堨溂氅�, 頃措嫻 鞗轨簮鞀ろ姼電� 90鞚� 霃欖晥 鞚挫毄 臧�電ロ暕雼堧嫟. 鞁れ嫓臧� 韱淀檾 彀胳棳毳� 鞗愴暊 瓴届毎 甑偞鞐愳劀電� 877-705-2976, 甑牅 鞝勴檾電� 201-689-8798搿� 鞝勴檾頃橂┐ 霅╇媹雼�.
Codexis (NASDAQ : CDXS), fournisseur de solutions enzymatiques pour la fabrication th茅rapeutique, a pr茅vu l'annonce des r茅sultats financiers du deuxi猫me trimestre 2025 pour le 13 ao没t 2025, apr猫s la cl么ture du march茅.
L'entreprise organisera une conf茅rence t茅l茅phonique et une diffusion en direct 脿 16h30 ET pour discuter des r茅sultats et fournir des mises 脿 jour commerciales. Les investisseurs pourront acc茅der 脿 la diffusion en direct via le site web des relations investisseurs de Codexis, o霉 elle restera disponible pendant 90 jours. Pour participer 脿 l'appel en direct, les participants peuvent composer le 877-705-2976 (domestique) ou le 201-689-8798 (international).
Codexis (NASDAQ: CDXS), Anbieter enzymatischer L枚sungen f眉r die therapeutische Herstellung, hat die Ver枚ffentlichung der Finanzergebnisse f眉r das zweite Quartal 2025 f眉r den 13. August 2025, nach B枚rsenschluss, angek眉ndigt.
Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen und Gesch盲ftsaktualisierungen zu geben. Investoren k枚nnen 眉ber die Investor-Relations-Website von Codexis auf den Webcast zugreifen, der dort 90 Tage lang verf眉gbar bleibt. F眉r die Live-Telefonkonferenz k枚nnen Teilnehmer die Nummer 877-705-2976 (national) oder 201-689-8798 (international) w盲hlen.
- None.
- None.
REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the second quarter of 2025 on Wednesday, August 13, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company鈥檚 financial results and provide a business update.
Participants may access the live webcast on the聽, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver庐聽technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis鈩� manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis鈥� unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit聽.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
FAQ
When will Codexis (CDXS) report Q2 2025 earnings?
What time is the Codexis Q2 2025 earnings call?
How can I access Codexis' Q2 2025 earnings call?
How long will Codexis' Q2 2025 earnings webcast be available?
